• Built value marketing function from scratch by identifying, hiring, and managing an agency and developing a strategic plan and accompanying tactical plan to ensure successful launch of both rociletinib and rucaparib.• Developed and successfully executed tactical plan (including medical, legal, and regulatory review and OPDP strategy) that included both disease education and branded materials as well as both non-personal and personal promotion. Recognized by field for breadth and quality of tools as well as immediate availability post-launch.• Presented branding plan for hub services to CEO and received buy-in and support to execute plan in 2-3 months.• Collaborated with sales training and leadership to develop and implement access training plan for 100+ field staff. Received satisfaction ratings of 4.7/5.0 for training in post-launch meeting survey. • Selected by VP of Marketing to serve as key member of core launch team with accountability for managed care marketing related activities and input into key launch deliverables including overall brand strategy. • Identified need for and pursued VP-level initiative to lead global market access strategy for launch of rociletinib in Europe including launch sequencing, pricing strategy, and HTA strategy. Recognized by senior leadership for this initiative and invited to serve as core member of EU launch team.• Initiated partnership with medical affairs to convince senior leadership of importance of developing Global Value Dossier (GVD) for successful reimbursement and launch strategy in EU. Received buy-in from senior leadership to co-lead initiative and launch GVD within next 9 months, a process which typically takes 2+ years.

• Collaborated with nurse educator team to develop marketing strategy and tactical plan for Esbriet launch; created and delivered both disease education and Esbriet branded launch materials within one month of FDA approval.• Partnered with national account managers and key market access colleagues to create and deliver Payer Value Deck and Formulary Kit, as well as key targeted payer media tactics.• Entrusted to create and deliver time-sensitive marketing materials for mandatory hub targeting both HCPs and patients for Esbriet launch within first two months of hire. Received recognition from senior leadership for high quality output under aggressive timeline.• Problem-solved hub enrollment issues regularly in response to feedback from field and patient access team, with short and long-term solutions identified and implemented, sometimes within record-breaking 2-day turnaround.

• Led development of Kyprolis® payer value story messaging in preparation for launch, including message testing, to deliver a clear and targeted story that resonated with payers.• Created Kyprolis® Global Payer Plan to facilitate stronger collaboration and communication with Amgen affiliates and drive more effective implementation of Kyprolis® global market access strategy.• Spearheaded global reimbursement assessment for executive leadership to inform a key strategic life cycle management decision. Recommendation was accepted by executive leadership and implemented.• Analyzed health technology assessments, pricing, and reimbursement decision trends for oncology products in US, Europe, Canada, and Australia to support Kyprolis® global launch strategy and life cycle management.• Initiated cross-functional team to improve Kyprolis® returns process reducing turnaround time by 75%.• Managed critical 2014 operating plan budget request process for RAV division, a leadership role previously held by a Senior Director. Operating plan was accepted by executive leadership team and implemented.

• Created iPad-delivered disease education campaign to increase penetration of Pulmozyme® in key patient segments. Collaborated with sales force to address knowledge gaps among physician population.• Developed tactical launch plan including KPI metrics to determine campaign effectiveness and training plan to ensure sales force comfort and competency utilizing new iPad application.• Partnered with key functional areas: Market Planning and Marketing Science to develop KPI metrics; Training & Development to create sales training strategy; Interactive Marketing to design and implement campaign on iPad.

• Performed strategic analyses of a portfolio company’s options to advance its antibody platform toward clinical development. Completed market and competitor assessments and modeled investment scenarios. • Developed recommendations to maximize Essex’s return on investment and presented strategy to portfolio company Board of Directors and Essex partnership. Proposal was accepted and is currently being implemented.

• Developed and implemented new marketing strategy and created partnership with Juvenile Diabetes Research Foundation, resulting in 50% increase in patient newsletter circulation and improved patient health outcomes. • Developed relationships with key pharmaceutical, medical device, and biotechnology executives and physicians at global medical conferences in order to maintain thought leadership within industry.• Selected as Managing Editor of monthly industry newsletter distributed to over 200 companies; researched and wrote daily report on market and company impact of diabetes and obesity news.• Built detailed model of client’s potential entry into diabetes market, used to assess major acquisition.• Created in-depth financial modeling training program for all new hires and trained existing associates.

• Recognized as research associate on Institutional Investor’s #1 ranked “All-America Research Team” for Media.• Conceived and researched sector-wide and company-specific investment ideas that generated majority of proprietary trading revenue for Media sector.• Researched and wrote initiation reports for Moody’s, Monster, RR Donnelley, and Dice in addition to over 300 detailed earnings notes and research reports on companies in the Media sector.• Presented and advocated investment ideas to sales force, traders, and clients (mutual, pension and hedge funds). • Built and maintained detailed forecasting, company valuation, and industry models.

• Recognized as research associate on Institutional Investor’s #1 ranked “All-America Research Team” for Media.• Conceived and researched sector-wide and company-specific investment ideas that generated majority of proprietary trading revenue for Media sector.• Researched and wrote initiation reports for Moody’s, Monster, RR Donnelley, and Dice in addition to over 300 detailed earnings notes and research reports on companies in the Media sector.• Presented and advocated investment ideas to sales force, traders, and clients (mutual, pension and hedge funds). • Built and maintained detailed forecasting, company valuation, and industry models.

• Researched and summarized pending healthcare legislation (e.g. Health Savings Accounts and Drug Safety)• Projected market impact of pending federal rulemaking and legislation and FDA reviews• Developed risk analysis model for national Medicaid spending and coverage of Xopenex • Wrote weekly research reports that were distributed to Lehman clients and Lehman analysts• Performed in-depth news search and analysis of current healthcare and pharmaceutical policy issues

• Developed list of over 100 target clients for the building products and materials group • Managed data for analysis of REITs and other real estate companies• Organized schedule of financial data regarding 100 largest U.S. homebuilders• Updated list of private equity investors in the aerospace and defense industries for the corporate finance group

• Researched proposed science and space legislation; Drafted position memos on prospective legislation for the Senator

• Received Recognition for Outstanding Scientific Contribution (2002 & 2003)• Cloned vectors for gene therapy of the genetic disorder, Beta-Thalassemia; wrote and presented research papers

• One of three students selected nationally for Biological Research Program